884
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

ORCID Icon, , , , &
Article: CRC38 | Received 03 Mar 2022, Accepted 11 Oct 2022, Published online: 09 Nov 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.